Cieri N, Maurer K, Wu C
Cancer Res. 2021; 81(17):4373-4384.
PMID: 34108142
PMC: 8416782.
DOI: 10.1158/0008-5472.CAN-21-0301.
Singh N, Shi J, June C, Ruella M
Curr Hematol Malig Rep. 2017; 12(6):522-529.
PMID: 29039115
PMC: 5709224.
DOI: 10.1007/s11899-017-0417-7.
Gaballa A, Sundin M, Stikvoort A, Abumaree M, Uzunel M, Sairafi D
Int J Mol Sci. 2016; 17(10).
PMID: 27727179
PMC: 5085737.
DOI: 10.3390/ijms17101705.
Poon L, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M
Biol Blood Marrow Transplant. 2013; 19(7):1059-64.
PMID: 23644077
PMC: 8439154.
DOI: 10.1016/j.bbmt.2013.04.014.
Rager A, Porter D
Ther Adv Hematol. 2013; 2(6):409-28.
PMID: 23556106
PMC: 3573422.
DOI: 10.1177/2040620711412416.
Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report.
Hamilton B, Vereb G, Copelan E
J Med Case Rep. 2013; 7:18.
PMID: 23316877
PMC: 3562165.
DOI: 10.1186/1752-1947-7-18.
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
Brentjens R, Curran K
Hematology Am Soc Hematol Educ Program. 2012; 2012:143-51.
PMID: 23233573
PMC: 5536093.
DOI: 10.1182/asheducation-2012.1.143.
Nonengraftment haploidentical cellular therapy for hematologic malignancies.
Reagan J, Fast L, Winer E, Safran H, Butera J, Quesenberry P
Adv Hematol. 2012; 2012:784213.
PMID: 22312367
PMC: 3270515.
DOI: 10.1155/2012/784213.
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.
Deol A, Lum L
Cancer Treat Rev. 2010; 36(7):528-38.
PMID: 20381970
PMC: 2921454.
DOI: 10.1016/j.ctrv.2010.03.004.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Bishop M, Dean R, Steinberg S, Odom J, Pavletic S, Chow C
Ann Oncol. 2008; 19(11):1935-40.
PMID: 18684698
PMC: 2733078.
DOI: 10.1093/annonc/mdn404.
Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model.
Shapira M, Hirshfeld E, Weiss L, Zeira M, Kasir J, Or R
Cancer Immunol Immunother. 2005; 54(4):383-8.
PMID: 15692848
PMC: 11041982.
DOI: 10.1007/s00262-004-0614-9.
Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.
Slavin S
Int J Hematol. 2003; 78(3):195-207.
PMID: 14604277
DOI: 10.1007/BF02983795.
Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation.
Takatsuki H, Yufu Y, Tachikawa Y, Uike N
Int J Hematol. 2002; 75(3):298-301.
PMID: 11999359
DOI: 10.1007/BF02982045.
Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park S, Min W, Yang I, Kim H, Min C, Eom H
Korean J Intern Med. 2001; 15(3):224-31.
PMID: 11242811
PMC: 4531771.
DOI: 10.3904/kjim.2000.15.3.224.
Graft versus leukemia.
Butturini A, Gale R
Immunol Res. 1992; 11(1):24-33.
PMID: 1602180
DOI: 10.1007/BF02918605.
